Meta-analysis of the effect of basiliximab on renal graft rejection and survival

Objective To study the effect of basiliximab,an anti-IL-2R monoclonal antibody,on the prevention of acute rejection and promoting graft survival in renal allograft recipients.Methods Published literature regarding the effects of basiliximab used for the prevention of acute rejection and promoting renal graft survival was reviewed,and Meta analysis was employed to analyze the results.Odds ratio(OR)and its 95% confidence interval(95%CI)were used as the parameters to evaluate the therapeutic effects.The statistical analyses were performed with RevMan 4.2 software.Results A total of 13 pertinent research articles were reviewed,including 2 papers written by Chinese authors and 11 by foreign authors.Meta-analysis of pooled results indicated that basiliximab prevented the recipients of kidney transplantation from acute rejection effectively with half-year prevention of OR 0.49 and 95%CI 0.28-0.87(P=0.01),and one-year prevention of OR 0.48,95%CI 0.35-0.65(P0.01).It was revealed that basiliximab could reduce the incidence of acute rejection by 51% in half year and 52% in one year.No statistical difference of graft survival was found between basiliximab and control group(OR 1.58,95%CI 0.92-2.71,P=0.10),implying that basiliximab did not throw an influence on graft survival.Conclusions Basiliximab may effectively prevent the recipients of kidney transplantation from acute rejection.No statistical difference of graft survival exists between the patients receiving basiliximab treatment and control group.